IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 93.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 387,237 shares of the company's stock after acquiring an additional 186,767 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd owned approximately 0.10% of Recursion Pharmaceuticals worth $2,048,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently bought and sold shares of RXRX. Softbank Group CORP. purchased a new position in Recursion Pharmaceuticals during the 4th quarter valued at about $99,152,000. Novo Holdings A S purchased a new position in Recursion Pharmaceuticals during the 4th quarter valued at about $68,375,000. Vanguard Group Inc. grew its stake in Recursion Pharmaceuticals by 40.1% during the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock valued at $229,908,000 after acquiring an additional 9,737,196 shares in the last quarter. Norges Bank purchased a new position in Recursion Pharmaceuticals during the 4th quarter valued at about $23,429,000. Finally, ARK Investment Management LLC grew its stake in Recursion Pharmaceuticals by 7.6% during the 1st quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company's stock valued at $184,174,000 after acquiring an additional 2,469,104 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.
Recursion Pharmaceuticals Price Performance
Shares of RXRX traded down $0.05 during mid-day trading on Wednesday, hitting $5.48. The company's stock had a trading volume of 17,960,051 shares, compared to its average volume of 30,745,180. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36. The company has a quick ratio of 4.11, a current ratio of 4.11 and a debt-to-equity ratio of 0.02. The stock's 50-day moving average is $5.34 and its two-hundred day moving average is $5.93.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 78.11%. The business had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. During the same period in the prior year, the company posted ($0.40) earnings per share. The firm's revenue was up 33.3% compared to the same quarter last year. Sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.
Analyst Ratings Changes
RXRX has been the subject of several recent research reports. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, July 8th. Morgan Stanley initiated coverage on Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price target for the company. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $7.00.
View Our Latest Stock Analysis on RXRX
About Recursion Pharmaceuticals
(
Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
See Also
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
